APL-9

DB16460InvestigationalSmall molecule

APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. It shares the same mechanism... It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

Mechanism: APL-9 broadly inhibits the complement cascade through specific targeting and inhibition of complement C3. This inhibition dampens downstream inflammatory processes.
Curator reviewed
Code names: APL-9

Resolves to

Targets

P01024C3

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with APL-9, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account